Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects

• Published in: Journal of clinical lipidology Vol. 14; no. 1; pp. 77 - 87
• Main Authors: Taskinen, Marja-Riitta, Björnson, Elias, Andersson, Linda, Kahri, Juhani, Porthan, Kimmo, Matikainen, Niina, Söderlund, Sanni, Pietiläinen, Kirsi, Hakkarainen, Antti, Lundbom, Nina, Nilsson, Ralf, Ståhlman, Marcus, Adiels, Martin, Parini, Paolo, Packard, Chris, Borén, Jan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2020
• Subjects: apoB; Apolipoprotein C3; Atherogenic dyslipidemia; atherosclerotic cardiovascular-disease; atorvastatin; bile-acid; Cell and Molecular Biology; Cell- och molekylärbiologi; cholesterol; De novo lipogenesis; Evolocumab; Farmakologi och toxikologi; fat; fat-content; hmg-coa reductase; hypertriglyceridemia; Liver; Liver fat; metabolism; PCSK9; Pharmacology & Pharmacy; Pharmacology and Toxicology; Postprandial lipids; precursors; Remnant lipoproteins; risk-factor; stable-isotope; Remnant lipoproteins; Apolipoprotein C3; Atherogenic dyslipidemia; Postprandial lipids; Liver fat; Evolocumab; De novo lipogenesis; PCSK9; apoB

Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) significantly lower the levels of low-density lipoprotein and very-low-density lipoproteins (VLDL), but their effect on postprandial lipoprotein metabolism in dyslipidemic subjects is unclear. This study aimed to investig...